These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31792037)

  • 1. Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study.
    von Mehren M; George S; Heinrich MC; Schuetze SM; Yap JT; Yu JQ; Abbott A; Litwin S; Crowley J; Belinsky M; Janeway KA; Hornick JL; Flieder DB; Chugh R; Rink L; Van den Abbeele AD
    Clin Cancer Res; 2020 Apr; 26(8):1837-1845. PubMed ID: 31792037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors.
    Italiano A; Chen CL; Sung YS; Singer S; DeMatteo RP; LaQuaglia MP; Besmer P; Socci N; Antonescu CR
    BMC Cancer; 2012 Sep; 12():408. PubMed ID: 22974104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
    Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
    Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors.
    Belinsky MG; Rink L; Flieder DB; Jahromi MS; Schiffman JD; Godwin AK; von Mehren M
    Genes Chromosomes Cancer; 2013 Feb; 52(2):214-24. PubMed ID: 23109135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
    Boikos SA; Pappo AS; Killian JK; LaQuaglia MP; Weldon CB; George S; Trent JC; von Mehren M; Wright JA; Schiffman JD; Raygada M; Pacak K; Meltzer PS; Miettinen MM; Stratakis C; Janeway KA; Helman LJ
    JAMA Oncol; 2016 Jul; 2(7):922-8. PubMed ID: 27011036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
    Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations.
    Pantaleo MA; Lolli C; Nannini M; Astolfi A; Indio V; Saponara M; Urbini M; La Rovere S; Gill A; Goldstein D; Ceccarelli C; Santini D; Rossi G; Fiorentino M; Di Scioscio V; Fusaroli P; Mandrioli A; Gatto L; Catena F; Basso U; Ercolani G; Pinna AD; Biasco G
    Genet Med; 2015 May; 17(5):391-5. PubMed ID: 25188872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST.
    Pantaleo MA; Astolfi A; Urbini M; Nannini M; Paterini P; Indio V; Saponara M; Formica S; Ceccarelli C; Casadio R; Rossi G; Bertolini F; Santini D; Pirini MG; Fiorentino M; Basso U; Biasco G;
    Eur J Hum Genet; 2014 Jan; 22(1):32-9. PubMed ID: 23612575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA.
    Beadling C; Patterson J; Justusson E; Nelson D; Pantaleo MA; Hornick JL; Chacón M; Corless CL; Heinrich MC
    Cancer Med; 2013 Feb; 2(1):21-31. PubMed ID: 24133624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Succinate dehydrogenase-deficient GISTs are characterized by IGF1R overexpression.
    Chou A; Chen J; Clarkson A; Samra JS; Clifton-Bligh RJ; Hugh TJ; Gill AJ
    Mod Pathol; 2012 Sep; 25(9):1307-13. PubMed ID: 22555179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
    Ganjoo KN; Villalobos VM; Kamaya A; Fisher GA; Butrynski JE; Morgan JA; Wagner AJ; D'Adamo D; McMillan A; Demetri GD; George S
    Ann Oncol; 2014 Jan; 25(1):236-40. PubMed ID: 24356634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry study.
    Tsai HJ; Shan YS; Yang CY; Hsiao CF; Tsai CH; Wang CC; Lin MT; Ting CF; Chan DC; Chen TH; Yen CC; Chen YY; Lin HY; Yeh TS; Ho CL; Shieh TY; Bai LY; Hsu JT; Chen IS; Chen LT; Yeh CN;
    BMC Cancer; 2024 Jul; 24(1):828. PubMed ID: 38992597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
    Heinrich MC; Rankin C; Blanke CD; Demetri GD; Borden EC; Ryan CW; von Mehren M; Blackstein ME; Priebat DA; Tap WD; Maki RG; Corless CL; Fletcher JA; Owzar K; Crowley JJ; Benjamin RS; Baker LH
    JAMA Oncol; 2017 Jul; 3(7):944-952. PubMed ID: 28196207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
    Van den Abbeele AD; Gatsonis C; de Vries DJ; Melenevsky Y; Szot-Barnes A; Yap JT; Godwin AK; Rink L; Huang M; Blevins M; Sicks J; Eisenberg B; Siegel BA
    J Nucl Med; 2012 Apr; 53(4):567-74. PubMed ID: 22381410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
    Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
    Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
    Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
    Kang YK; George S; Jones RL; Rutkowski P; Shen L; Mir O; Patel S; Zhou Y; von Mehren M; Hohenberger P; Villalobos V; Brahmi M; Tap WD; Trent J; Pantaleo MA; Schöffski P; He K; Hew P; Newberry K; Roche M; Heinrich MC; Bauer S
    J Clin Oncol; 2021 Oct; 39(28):3128-3139. PubMed ID: 34343033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
    Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation.
    Miettinen M; Killian JK; Wang ZF; Lasota J; Lau C; Jones L; Walker R; Pineda M; Zhu YJ; Kim SY; Helman L; Meltzer P
    Am J Surg Pathol; 2013 Feb; 37(2):234-40. PubMed ID: 23282968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction.
    Nannini M; Astolfi A; Paterini P; Urbini M; Santini D; Catena F; Indio V; Casadio R; Pinna AD; Biasco G; Pantaleo MA
    Future Oncol; 2013 Jan; 9(1):121-6. PubMed ID: 23252569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.